The research team is now monitoring 12 more participants who received higher doses of 150,000 and 250,000 cells. If no safety ...

The overall dry AMD market size in the US is anticipated to increase, due to the uptake of recently approved therapies, the launch of emerging therapies such as Gildeuretinol (Alkeus Pharmaceuticals), ...

A new approach pioneered by Aalto University scientists uses controlled warmth to trigger self-repair within retinal cells ...

A first-of-its-kind trial is testing adult stem cell transplants for advanced dry macular degeneration. Early results show ...

The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...

Age-related macular degeneration (AMD) is one of the leading causes of vision loss among adults over 65. This condition ...

University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly protect against age-related macular degeneration (AMD)-like pathology in preclinical ...

ANNX advances tanruprubart for Guillain-Barré syndrome, with an EMA filing planned for January 2026 and ongoing FDA ...

In a first-in-human phase 1/2a clinical trial, researchers used adult stem cells to help restore vision in people with age-related macular degeneration. In the United States, age-related macular degen ...

No changes in protocol recommended for LUGANO and LUCIA clinical trials –– Masked safety data continues to show no safety signals, consistent ...

Menlo Park resident Carmen Caricchio is on a quest to cure childhood inherited retinal diseases, a group of rare conditions that cause the degeneration of the retina and can lead to vision impairment ...